Alterity Therapeutics Issues 18M Options, Signaling Near 100% Potential Dilution
summarizeResume
Alterity Therapeutics has issued a substantial number of unlisted options under an employee incentive scheme. While not directly granted to key management personnel, the 18 million options represent a potential increase of nearly 100% in the company's US-equivalent shares outstanding, based on the current market capitalization and stock price. This level of potential dilution is highly significant and could materially impact the value of existing shares. The options' deeply in-the-money exercise price of AUD 0.008, compared to the current US stock price of $3.4, makes their eventual exercise highly probable, posing a considerable overhang on the stock.
check_boxEvenements cles
-
Issuance of Unlisted Options
Alterity Therapeutics issued 18,000,000 unlisted options on January 15, 2026.
-
Employee Incentive Scheme
The options were granted under an employee incentive scheme, not directly to key management personnel.
-
Significant Potential Dilution
If exercised, these options represent a potential increase of nearly 100% in the company's US-equivalent shares outstanding, based on the current market capitalization and stock price.
-
Deeply In-The-Money Options
The options have an exercise price of AUD 0.008 and expire in 2031, making them deeply in-the-money compared to the current US stock price of $3.40.
auto_awesomeAnalyse
Alterity Therapeutics has issued a substantial number of unlisted options under an employee incentive scheme. While not directly granted to key management personnel, the 18 million options represent a potential increase of nearly 100% in the company's US-equivalent shares outstanding, based on the current market capitalization and stock price. This level of potential dilution is highly significant and could materially impact the value of existing shares. The options' deeply in-the-money exercise price of AUD 0.008, compared to the current US stock price of $3.4, makes their eventual exercise highly probable, posing a considerable overhang on the stock.
Au moment de ce dépôt, ATHE s'échangeait à 3,40 $ sur NASDAQ dans le secteur Life Sciences, pour une capitalisation boursière d'environ 61,8 M $. La fourchette de cours sur 52 semaines allait de 2,52 $ à 7,00 $. Ce dépôt a été évalué avec un sentiment de marché négatif et un score d'importance de 9 sur 10.